Recent improvements in polio and pertussis vaccination policy in Israel, 2005

Israel Medical Association Journal

Volumn 8, Issue 5, 2006, Pages 319-321

  Rishpon, Shmuel ^a,b  

^a MINISTRY OF HEALTH   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

Author keywords

Immunization policy; Israel; Pertussis; Polio

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA TETANUS TOXOID; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE;

AGE DISTRIBUTION; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; COST BENEFIT ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; EPIDEMIC; ERADICATION THERAPY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; INFECTION SENSITIVITY; ISRAEL; MASS IMMUNIZATION; PERTUSSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TETANUS PROPHYLAXIS; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; WHOLE CELL;

ADOLESCENT; CHILD; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; ISRAEL; PERTUSSIS VACCINE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; WHOOPING COUGH;

EID: 33744467051     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Swartz TA, Handsher R, Manor Y, et al. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. Vaccine 1998;16:2090-5.
2. Shulman LM, Handsher R, Yang CF, et al. Resolution of the pathways of poliovirus type 1 transmission during an outbreak. Vaccine 1993;11:75-81.
3. Slater PE, Orenstein WE, Morag A, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990;335:1192-8.
4. WHO. Global Poliomyelitis Eradication Initiative: number of endemic countries. Wkly Epidemiol Rec 2002;177:325-8.
5. Olen MK, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull WHO 2004;82:16-23.
6. Shulman LM, Manor Y, Handsher R, et al. Molecular and antigenic characterizations of a highly evolved derivative of the type II polio vaccine strain isolated from sewage in Israel. J Clin Microbiol 2000;38:3729-34.
7. Sutter RW, Caceres VM, Mas Lago P. The role of routine polio immunization in the post-certification era. Bull WHO 2004;82:31-9.
8. Cherry JD. In: The Epidemiology of Pertussis and Pertussis Immunization in the United Kingdom and the United States: A Comparative Study. Chicago: Year Book Medical Publishers, 1984:1-78.
9. Klement E, Uliel L, Engel I, et al. An outbreak of pertussis among young Israeli soldiers. Epidemiol Infect 2003;131:1049-54.
10. Guris PM, Strebel B, Bardenheier M, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999;28:1230-7.
11. De Melker HE, Conyn Van Spaendonck MA, Rumke HC, van Wijngaarden JK, Mooi FR, Schellekens JF. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis 1997;3:175-8.
12. Arav-Boger R, Ashkenazi S, Gdalevich M, Cohen D, Danon YL. Seroprevalence of pertussis antibodies among adolescents in Israel. IMAJ 2000;2:174-7.
13. Baron S, Njamkepo E, Grimprel EJ, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine vaccination. Pediatr Infect Dis J 1998;17:412-18.
14. ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis Vaccine. June 30, 2005. http://www.cdc.gov/nip/pr/ pr_tdap_jun2005.htm